FAM152A Activators encompass a range of chemical compounds that indirectly enhance the functional activity of FAM152A through modulation of intracellular signaling pathways, primarily those involving cyclic adenosine monophosphate (cAMP). Forskolin, a diterpene, directly stimulates adenylate cyclase, thereby increasing cAMP levels and activating protein kinase A (PKA). This activation can lead to phosphorylation of substrate proteins that are part of the FAM152A functional network, thus enhancing FAM152A's activity. Similar in their effects, Rolipram and IBMX raise intracellular cAMP levels by inhibiting phosphodiesterases, with Rolipram being specific to PDE4 and IBMX acting more broadly. The increased cAMP then activates PKA, which could phosphorylate and activate proteins associated with FAM152A, boosting its activity. Likewise, endogenous compounds such as PGE2, epinephrine, and isoproterenol bind to their respective receptors, which signal through G proteins to increase cAMP and activate PKA, leading to a cascade of phosphorylation events that can enhance FAM152A's function.
The influence of FAM152A activators extends to other endogenous signaling molecules such as glucagon, dopamine, and histamine, which all enhance FAM152A activity by stimulating adenylate cyclase through their receptors, increasing cAMP, and subsequently activating PKA. Anagrelide, another activator, operates by inhibiting phosphodiesterase-3, thereby raising cAMP levels and enhancing FAM152A activity through activated PKA and its downstream effects on FAM152A-associated proteins. Furthermore, the exogenous compound cholera toxin irreversibly activates the Gs alpha subunit, resulting in sustained cAMP production and potential enhancement of FAM152A function through PKA-driven signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) inhibits phosphodiesterases, preventing the breakdown of cAMP. Elevated cAMP levels can lead to activation of PKA, which can phosphorylate and activate MADP-1. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to and activates adrenergic receptors, which stimulate adenylyl cyclase to produce cAMP. The increase in cAMP activates PKA, which can then activate MADP-1 by phosphorylation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its receptors, which can signal through G-proteins to activate adenylyl cyclase, increasing cAMP levels. This elevation in cAMP can result in the activation of PKA, which may lead to the activation of MADP-1. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can bind to its G-protein-coupled receptors, leading to the activation of adenylyl cyclase and an increase in cAMP levels. The resulting activation of PKA can lead to the phosphorylation and activation of MADP-1. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine binds to its receptors, particularly D1-like receptors, which can stimulate adenylyl cyclase, leading to an increase in cAMP and subsequent activation of PKA. PKA can phosphorylate and activate MADP-1. | ||||||
PACAP(6-38) | 137061-48-4 | sc-391136 sc-391136A | 500 µg 1 mg | $540.00 $932.00 | ||
Pituitary adenylate cyclase-activating polypeptide (PACAP-38) binds to its receptors, leading to adenylyl cyclase activation, increased cAMP, and PKA activation. PKA can then phosphorylate and functionally activate MADP-1. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase III, leading to increased cAMP and activation of PKA. PKA can then phosphorylate and activate MADP-1. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram selectively inhibits phosphodiesterase IV, which leads to increased levels of cAMP in cells, subsequently activating PKA. PKA can phosphorylate MADP-1, leading to its activation. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a dual inhibitor of phosphodiesterase III and IV, leading to increased cAMP levels and PKA activation. PKA can then phosphorylate and activate MADP-1. | ||||||